Hong Kong Pharma Digital Technology Holdings Limited: 5%+ holders

Who owns Cellyan Biotechnology Co., Ltd?

Liying Wang also filed stake reports on 1 other company ↓

Hong Kong Pharma Digital Technology Holdings Limited has 1 Schedule 13D or 13G filing on record since 2025-11-12. 1 holder's latest filing reports 5% or more of ordinary shares, par value $0.001 per share. Each figure below is the holder's own, as filed, with the filing linked.

Holders

Swipe the table sideways to see every column.

Want the whole picture on Hong Kong Pharma Digital Technology Holdings Limited?

Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC

A Full Report on Hong Kong Pharma Digital Technology Holdings Limited: verified, sourced, every claim cited, ready in a few minutes. See pricing.

What the Full Report on Hong Kong Pharma Digital Technology Holdings Limited covers

1. The Short Answer

2. Which Company This Is

3. What They Do, And How The Money Works

4. Who Runs It, And How To Reach Them

5. The Money: Funding, Valuation, Runway

6. Who Pays Them, And Who They Are Up Against

7. Warning Bells

8. Sources

   7 cited sources found

Plus the sections for what you are deciding, which you pick after ordering.

Order Full ReportSee a sample report

A real finished report, first screen. Opens in a new tab.

Purpose of Transaction (Item 4)

Liying Wang

Effective September 9, 2025, the board ("Board") of directors of the Company appointed Mr. Zhou Mike Yao as an independent director of the Company and a member of the nomination committee of the Board. On October 6, 2025, the Board of the Company received and accepted the resignation of Mr. Wong Lap Sun from his position as Chief Executive Officer, the resignation of Mr. Zhifang Zhang from his position as Executive Director, and the resignation of Mr. Kwok Man Bun from his position as Chief Financial Officer effective immediately. Previously on April 30, 2025, the Board received and accepted the resignation of Ms. Yingying Li from her position as Chief Operating Officer, effective immediately. Effective on October 6, 2025, the Board appointed Mr. Chenyu Liang as Director and Chief Executive Officer, Ms. Shu Liu as Chief Financial Officer and Mr. Zifeng Wang as Chief Strategy Officer of the Company. The Reporting Persons purchased the Shares based on the Reporting Persons' belief that the Shares, when purchased, represented an attractive investment opportunity. As a result of its ability to vote 65% of all the share capital of the Company, the Reporting Persons have the power to significantly influence the election of directors and all other matters that would require the vote of the outstanding share capital of the Company. Subject to the restrictions on transfer arising under US securities laws (including, for the avoidance of doubt, Rule 144 under the Securities Act), …The first part of Item 4 of the SCHEDULE 13D filed 2025-11-12; the filing has the rest

Timeline

Swipe the table sideways to see every column.

Also on the record for Hong Kong Pharma Digital Technology Holdings Limited

Swipe the table sideways to see every column.

Where this comes from

Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.

Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.

All recent stakesThat week's stakes